The estimated Net Worth of Benjamin J. Hindson is at least $21.2 Million dollars as of 22 August 2024. Benjamin Hindson owns over 4,351 units of 10x Genomics stock worth over $7,640,058 and over the last 5 years he sold TXG stock worth over $11,881,978. In addition, he makes $1,669,190 as President, Co-Founder, Chief Scientific Officer, and Director at 10x Genomics.
Sign up
Benjamin Hindson TXG stock SEC Form 4 insiders trading
Benjamin has made over 44 trades of the 10x Genomics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,351 units of TXG stock worth $98,028 on 22 August 2024.
The largest trade he's ever made was exercising 113,920 units of 10x Genomics stock on 28 December 2021 worth over $129,869. On average, Benjamin trades about 23,466 units every 34 days since 2019. As of 22 August 2024 he still owns at least 345,704 units of 10x Genomics stock.
You can see the complete history of Benjamin Hindson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Benjamin Hindson biography
Dr. Benjamin J. Hindson serves as President, Co-Founder, Chief Scientific Officer, Director of the Company. He co-founded 10x Genomics in July 2012, has served as our Chief Scientific Officer and President since October 2012 and has served on our board of directors since July 2012. Dr. Hindson served as our President of Technology and Treasurer from July 2012 until October 2012 and as our Secretary from October 2012 until April 2014. Prior to co-founding our company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia.
What is the salary of Benjamin Hindson?
As the President, Co-Founder, Chief Scientific Officer, and Director of 10x Genomics, the total compensation of Benjamin Hindson at 10x Genomics is $1,669,190. There are 1 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
How old is Benjamin Hindson?
Benjamin Hindson is 45, he's been the President, Co-Founder, Chief Scientific Officer, and Director of 10x Genomics since 2014. There are 10 older and 5 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
What's Benjamin Hindson's mailing address?
Benjamin's mailing address filed with the SEC is 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Insiders trading at 10x Genomics
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F..., and Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
What does 10x Genomics's logo look like?
Complete history of Benjamin Hindson stock trades at 10x Genomics
10x Genomics executives and stock owners
10x Genomics executives and other stock owners filed with the SEC include:
-
Serge Saxonov,
Chief Executive Officer, Co-Founder, Director -
Benjamin Hindson,
President, Co-Founder, Chief Scientific Officer, Director -
Sridhar Kosaraju,
Independent Director -
Shehnaaz Suliman,
Independent Director -
Eric Whitaker,
General Counsel -
Bryan Roberts,
Independent Director -
Dr. Serge Saxonov Ph.D.,
Co-Founder, CEO & Director -
Justin McAnear,
Chief Financial Officer -
Dr. Benjamin J. Hindson Ph.D.,
Co-Founder, Pres, Chief Scientific Officer & Director -
Bradford J. Crutchfield,
Chief Commercial Officer -
Ruth De Backer,
Chief Bus. Officer -
Justin J. McAnear,
Chief Financial Officer -
John Stuelpnagel,
Independent Chairman of the Board -
Mathai Mammen,
Independent Director -
Kimberly Popovits,
Independent Director -
Bradford Crutchfield,
Chief Commercial Officer -
Jean Philibert,
Chief People Officer -
Sam Ropp,
Sr. VP of Global Sales -
Jonathan Schimmel,
VP of Global Support & Sales Operations -
Eric S. Whitaker,
Gen. Counsel -
Cassie Corneau,
Mang. of Investor Relations and Strategic Fin. -
Paul W. Wyatt,
Sr. VP of Operations -
Capital Management, Llc Pal...,
-
Associates Vi, L.P.Venrock ...,
-
Vision Fund (Aiv M2) L.P.Sb...,
-
Capital Management I, Llc F...,
-
Sarah A. Teichmann,
-
James Wilbur,
Chief Commercial Officer -
Alan Mateo,